• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATH

ALTERITY THERAPEUTICS LIMITED

0.00% ! 1.1¢
Market Cap $100.4M  !

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
ATH
News, articles and interviews
2
18:01 118 41K
18:01 Last post  MrLearner Comments Created with Sketch.  118  Views Created with Sketch.  41K 
ATH
Stock price - ATH/ATHE
29 30 31
14:28 1.8K 581K
14:28 Last post  MrLearner Comments Created with Sketch.  1.8K  Views Created with Sketch.  581K 
ATH
Glucose metabolism and iron accumulation in PD
08/06/25 0 403
TRENDING NEWS

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

NEWS
13 Jun 2025
08/06/25 Last post  pivalde Comments Created with Sketch.  0  Views Created with Sketch.  403 
ATH
Cortical iron accumulation / memory
07/06/25 3 1.7K
07/06/25 Last post  pivalde Comments Created with Sketch.  3  Views Created with Sketch.  1.7K 
ATH
New diagnostic methods for MSA and PD
30/05/25 4 1.8K
30/05/25 Last post  itsagas Comments Created with Sketch.  4  Views Created with Sketch.  1.8K 
ATH
Short activity
29/05/25 4 1.8K
29/05/25 Last post  MrLearner Comments Created with Sketch.  4  Views Created with Sketch.  1.8K 
ATH 26/05/25 3 1.9K
26/05/25 Last post  GroRob Comments Created with Sketch.  3  Views Created with Sketch.  1.9K 
ATH
Donanemab approved in Australia for treatment of Alzheimer's disease
22/05/25 0 417
22/05/25 Last post  HazASX Comments Created with Sketch.  0  Views Created with Sketch.  417 

See All Discussions arrow Created with Sketch.

Timeline

Change in substantial holding
23 May 08:20
 
Alterity Prominently Featured at International MSA Congress
12 May 09:54
 
Change in substantial holding
12 May 08:16
 
Alterity Phase 2 Data to be Featured at MSA Congress
07 May 13:00
 
Alterity Granted U.S. FDA Fast Track Designation for ATH434
05 May 08:53
 
Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 09:30
 
View More arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.1¢
Change
0.000(0.00%)
Mkt cap ! $100.4M
Open High Low Value Volume
1.0¢ 1.1¢ 1.0¢ $60.81K 5.737M

Buyers (Bids)

No. Vol. Price($)
37 16255465 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 1643984 2
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
Last
1.1¢
  Change
0.000 ( 4.76 %)
Open High Low Volume
1.1¢ 1.1¢ 1.0¢ 5122552
Last updated 15.59pm 13/06/2025 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.